Microdosing Semaglutide Chart: A Monthly Dose Guide For Josie Patients
Health & Wellness Editors
Website content is for informational purposes only and is not medical advice. Always talk with a licensed medical provider about your care options.
Compounded GLP-1 medications are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality before marketing. Compounded medications are not the same as FDA-approved generics. Josie is not a compounding pharmacy; if prescribed, compounded medications are prepared by a licensed compounding pharmacy.
GLP-1 medications are prescription drugs and carry serious risks, including a boxed warning for thyroid C-cell tumors. Do not use them if you or a family member has had medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Other reported risks include pancreatitis, gallbladder disease, kidney problems, and severe gastrointestinal reactions. Discuss the full risks with a licensed provider.
Individual results vary. No outcome is promised or guaranteed. Published weight-loss trial results come from FDA-approved brand-name products at their studied doses and do not transfer to compounded preparations. Microdosing is not an FDA-approved dosing regimen.
Wegovy and Ozempic are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Josie is not affiliated with, endorsed by, or sponsored by either company.
A semaglutide microdosing chart that supports comfort, longevity, and gentle month-to-month increases.
If your provider has put you on a microdose of compounded semaglutide for maintenance, a dosing chart makes the schedule easier to follow. Microdosing is not an FDA-approved dosing regimen, evidence for ultra-low-dose use is limited, and no dose schedule has been shown to prevent side effects such as nausea or bloating.
Unlike traditional protocols that begin at 0.25 mg weekly, microdosing may begin as low as 0.05 mg. This gives the body time to adjust before moving higher, which can make the experience feel more comfortable and sustainable.
This gradual approach is part of a broader hormone-aware GLP-1 microdosing strategy used during midlife metabolic changes.
What Is a Microdosing Semaglutide Chart?
A microdosing semaglutide chart is a step-by-step monthly dosing progression guide that starts low and increases gradually over time.
The goal is to help the body adjust comfortably, especially for patients who may be sensitive to GLP-1 medications or prone to nausea and digestive side effects. Instead of jumping to the standard starting dose right away, microdosing allows a slower on-ramp guided by a medical provider.
Sample Microdosing Semaglutide Chart
| Month | Dose | Purpose |
|---|---|---|
| Month 1 | 0.05–0.1 mg | Allow the body to adapt gently |
| Month 2 | 0.1–0.15 mg | Begin mild appetite regulation |
| Month 3 | 0.15–0.2 mg | Build tolerance gradually |
| Month 4 | 0.2–0.25 mg | Approach the standard starting dose |
| Month 5+ | 0.25 mg and above | Personalized with your provider |
This chart shows a gentle month-by-month progression. Dose increases are always customized by the provider and based on how the patient feels.
Microdose vs Standard Semaglutide Titration
Standard semaglutide protocols follow a fixed escalation schedule. A microdosing approach moves through smaller steps and allows more flexibility based on how the patient responds.
| Stage | Standard Protocol | Microdose Approach |
|---|---|---|
| Starting Dose | 0.25 mg weekly | 0.05–0.1 mg weekly |
| 4-Week Increase | 0.5 mg | 0.05–0.1 mg |
| 8-Week Increase | 1.0 mg | 0.1–0.15 mg |
| 12-Week Increase | 1.7 mg | 0.15–0.2 mg |
| Maintenance Range | 2.4 mg (FDA max) | 0.25 mg and above, provider-guided |
| Side Effect Risk | Higher during escalation | Lower with gradual approach |
Standard protocol doses reflect the FDA-approved titration schedule for Wegovy, which begins at 0.25 mg weekly and increases every four weeks. Microdose ranges represent provider-guided approaches outside of standard clinical protocols.
Why Follow a Semaglutide Microdosing Schedule?
GLP-1 medications can feel intense if the starting dose is too high. A gradual dosing schedule allows the digestive system and appetite signals to adapt at a comfortable pace. Microdose regimens have not been studied in trials, so no particular experience should be expected.
Benefits often include:
- Side effects such as nausea and bloating are still possible at any dose
- Smoother appetite regulation instead of sudden changes
- Better long-term consistency with treatment
- Greater comfort during dose adjustments
For many women in perimenopause and menopause, this slower progression can make the experience feel more manageable.
Semaglutide Microdosing + Healthy Habits = Long Term Wellness
Medication can support your goals. Healthy habits help you sustain them.
At Josie, we encourage focusing on simple foundations:
- Strength training at least twice per week to protect muscle and metabolism
- High-protein meals to support recovery and body composition
- Daily movement like walking, stretching, or low-impact cardio
- Hydration to support digestion and energy
- Consistent sleep to support hormones and appetite regulation
These habits do not make the medication “work.”
They help you feel better while you are on it.
Josie's Takeaways
- A microdosing semaglutide chart helps patients ease into treatment comfortably.
- Starting doses in the 0.05 to 0.10 mg range are sometimes used for maintenance. No trial has studied microdose regimens, so their effect on nausea or digestive side effects is not established.
- Month-by-month increases are often easier to tolerate than rapid titration.
- No benefit specific to perimenopause or menopause has been established for microdose regimens, which have not been studied in trials.
- Dosing should always be personalized with a licensed medical provider based on the patient's goals and biological makeup.
Explore Semaglutide Microdosing at Josie
Josie offers compounded semaglutide options for patients who prefer a gradual dosing approach.
At Josie, Dr. Ana Lisa Carr will be your supervising MD.
Further Reading
Scientific References
U.S. Food & Drug Administration. Wegovy (semaglutide) Prescribing Information: approved dosing and escalation schedule, contraindications, and the boxed warning for thyroid C-cell tumors.
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
Dushay J. GLP-1 microdosing is popular, but there is little evidence it works. STAT News, May 29, 2026.
ClinicalTrials.gov. Effectiveness of Microdosed GLP-1 in Improving Health (NCT07092605): registered trial of microdosed GLP-1 therapy, results pending.
U.S. Food & Drug Administration. Compounding and the FDA: questions and answers: compounded drugs are not FDA-approved, and the agency does not review them for safety, effectiveness, or quality before marketing.
Microdose GLP-1
Low-dose semaglutide or tirzepatide
$189/mo
For women who have finished or paused a full dose and want to hold their progress. A licensed provider sets your maintenance dose and adjusts it with you.
Start Your IntakeTakes about 5 minutes
Related Articles
Microdosing
$189/mo